BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 22098317)

  • 1. Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats.
    Yang YY; Lee TY; Huang YT; Chan CC; Yeh YC; Lee FY; Lee SD; Lin HC
    Liver Int; 2012 Jan; 32(1):48-57. PubMed ID: 22098317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis.
    Segarra G; Cortina B; Mauricio MD; Novella S; Lluch P; Navarrete-Navarro J; Noguera I; Medina P
    World J Gastroenterol; 2016 Dec; 22(48):10545-10556. PubMed ID: 28082806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis.
    Laleman W; Omasta A; Van de Casteele M; Zeegers M; Vander Elst I; Van Landeghem L; Severi T; van Pelt J; Roskams T; Fevery J; Nevens F
    Hepatology; 2005 Dec; 42(6):1382-90. PubMed ID: 16317694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.
    Reiberger T; Payer BA; Schwabl P; Hayden H; Horvatits T; Jäger B; Hummel T; Mitterhauser M; Trauner M; Fuhrmann V; Angermayr B; Peck-Radosavljevic M;
    Liver Int; 2013 Apr; 33(4):561-8. PubMed ID: 23331709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADMA and hepatic endothelial dysfunction in cirrhosis--the DDAH isoform is the key.
    Mookerjee RP; Balasubramaniyan V; Mehta G
    Liver Int; 2012 Aug; 32(7):1186; author reply 1187. PubMed ID: 22574915
    [No Abstract]   [Full Text] [Related]  

  • 6. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
    J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of proton pump inhibitor on hepatic vascular responsiveness and hemodynamics in cirrhotic rats.
    Hsin IF; Hsu SJ; Chuang CL; Huo TI; Huang HC; Lee FY; Ho HL; Chang SY; Lee SD
    J Chin Med Assoc; 2018 Jul; 81(7):585-592. PubMed ID: 29780000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal release of nitric oxide in the mesenteric artery in portal hypertension and cirrhosis: role of dimethylarginine dimethylaminohydrolase.
    Serna E; Mauricio MD; Lluch P; Segarra G; Cortina B; Lluch S; Medina P
    J Gastroenterol Hepatol; 2013 May; 28(5):880-6. PubMed ID: 23302093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
    Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
    J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of portal hypertension and hepatic blood flow in cirrhotic rats by oestrogen.
    Sakamoto M; Ueno T; Nakamura T; Sakata R; Hasimoto O; Torimura T; Sata M
    Eur J Clin Invest; 2005 Mar; 35(3):220-5. PubMed ID: 15733078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.
    Mookerjee RP; Mehta G; Balasubramaniyan V; Mohamed Fel Z; Davies N; Sharma V; Iwakiri Y; Jalan R
    J Hepatol; 2015 Feb; 62(2):325-31. PubMed ID: 25152204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension.
    Laviña B; Gracia-Sancho J; Rodríguez-Vilarrupla A; Chu Y; Heistad DD; Bosch J; García-Pagán JC
    Gut; 2009 Jan; 58(1):118-25. PubMed ID: 18829979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
    Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
    Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis.
    Yang YY; Huang YT; Lee KC; Lee FY; Lee TY; Hou MC; Lin HC; Lee SD
    Clin Sci (Lond); 2009 Jan; 116(1):71-9. PubMed ID: 18479249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension.
    Biecker E; Trebicka J; Kang A; Hennenberg M; Sauerbruch T; Heller J
    Liver Int; 2008 Mar; 28(3):331-8. PubMed ID: 18290775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
    Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
    World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
    Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
    J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of endothelin-1 on portal-systemic collaterals of common bile duct-ligated cirrhotic rats.
    Chan CC; Wang SS; Lee FY; Chang FY; Lin HC; Hou MC; Huang HC; Lee SD
    Eur J Clin Invest; 2004 Apr; 34(4):290-6. PubMed ID: 15086361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin E supplementation reverses renal altered vascular reactivity in chronic bile duct-ligated rats.
    Alcaraz A; Iyú D; Atucha NM; García-Estañ J; Ortiz MC
    Am J Physiol Regul Integr Comp Physiol; 2007 Apr; 292(4):R1486-93. PubMed ID: 17158269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.